Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Initiation on Imraldi® therapy after 18th October 2018, as part of routine treatment immediately after transitioning from at least 16 weeks' treatment with originator adalimumab (Humira®)
Availability of at least one Baseline disease score (i.e. within 16 weeks prior or up to 6 weeks post-initiation of Imraldi®)
Should provide informed consent to participate in the study
You may not be if
\- Unlikely to attend for regular clinic visits for the duration of study follow-up, in the opinion of the Investigator
Clareo Health | A Real-world Study of Imraldi® Use
